| Interventions: |
DRUG: Part A, Reference (D635 10/500mg, Astrazeneca)|DRUG: Part A, Reference (D635 10/500mg, Astrazeneca)|DRUG: Part B, Reference (D635 10/500mg, Astrazeneca)|DRUG: Part B, Reference (D635 10/500mg, Astrazeneca)
|
| Outcome Measures: |
Primary: Part A : Cmax under fasting condition, Maximum concentration of the dapagliflozin, 0(predose)~48 hours|Part A : Cmax under fasting condition, Maximum concentration of the metformin, 0(predose)~48 hours|Part A : AUClast under fasting condition, Area Under Curve(last) of the dapagliflozin, 0(predose)~48 hours|Part A : AUClast under fasting condition, Area Under Curve(last) of the metformin, 0(predose)~48 hours|Part B : Cmax under fed condition, Maximum concentration of the metformin, 0(predose)~48 hours|Part B : AUClast under fed condition, Area Under Curve(last) of the metformin, 0(predose)~48 hours | Secondary: Part A : AUCinf under fasting condition, Area Under Curve(infinit) of the dapagliflozin, 0(predose)~48 hours|Part A : AUCinf under fasting condition, Area Under Curve(infinit) of the metformin, 0(predose)~48 hours|Part A : Tmax under fasting condition, Time of maximum concentration of the dapagliflozin, 0(predose)~48 hours|Part A : Tmax under fasting condition, Time of maximum concentration of the metformin, 0(predose)~48 hours|Part A : t1/2 under fasting condition, Half life of the dapagliflozin, 0(predose)~48 hours|Part A : t1/2 under fasting condition, Half life of the metformin, 0(predose)~48 hours|Part B : AUCinf under fed condition, Area Under Curve(infinit) of the metformin, 0(predose)~48 hours|Part B : Tmax under fed condition, Time of Maximum concentration of the metformin, 0(predose)~48 hours|Part B : t1/2 under fed condition, Half life of the metformin, 0(predose)~48 hours
|
